ONCAlert | 2018 ASCO Annual Meeting

Lung Cancer MORE >>

A supplemental biologics license application has been accepted by the FDA seeking approval for the combination of nivolumab plus ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden  ≥10 mutations per megabase, according to Bristol-Myers Squibb, the manufacturer of both immune checkpoint inhibitors.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.